Guardant Health and OncoMed Pharmaceuticals will collaborate using Guardant Health’s digital sequencing technology to develop a custom blood test that looks for specific biomarkers relevant to OncoMed’s ongoing phase Ia/Ib trial of its anti-RSP03 antibody. RSPO3 gene overexpression, including RSPO3 gene fusions, appear to drive tumor growth in subsets of several cancers, including colon, ovarian,...
In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, Jacquelyn Cobb, managing editor, discuss the Sept. 23 meeting of the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, during which the panel voted in favor of Galleri, the multi-cancer detection test from GRAIL Inc., to become the first multi-cancer detection test to receive regulatory approval.
